QIAGEN Added to NASDAQ-100 Index
Dec 14 2009

QIAGEN Added to NASDAQ-100 Index

VENLO, The Netherlands, December 14, 2009 - QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that its common shares will be included in the NASDAQ-100 Index effective as of the start of trading on December 21, 2009. The NASDAQ-100 Index comprises the top 100 non-financial securities listed on The NASDAQ Stock Market based on market capitalization. Launched in January 1985, the NASDAQ-100 Index includes companies across major industry groups.

"The addition of our securities to the NASDAQ-100 Index reflects our strong growth, consistent performance and significant value creation", said Peer M. Schatz, CEO of QIAGEN. "We are honoured to be added to this elite set of companies". QIAGEN's common shares have been trading on The NASDAQ Stock Market since the Company's initial public offering on June 28, 1996.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.


Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing, molecular diagnostics, personalized healthcare and companion diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Annual Report on Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.


Share this page